Shots:

• Dragonfly to receive $475M as up front and is eligible to receive development- regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program- including its extended half-life cytokine DF6002
• BMS will be responsible for the development & commercialization of DF6002 and its related products- including strategic decisions- regulatory responsibilities- funding- and manufacturing
• DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein- currently being evaluated in P-I/II study for patients with advanced solid tumors- which began in Jul’2020. Additionally- BMS plans to advance the research and development of DF6002 in oncology and hematology

Click here ­to­ read full press release/ article 

 Ref: PRNewswire | Image: BMS